Osteonecrosis of the jaws induced by anti-RANK ligand therapy

Abstract Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear fa...

Full description

Saved in:
Bibliographic Details
Published in:British journal of oral & maxillofacial surgery 2010-04, Vol.48 (3), p.221-223
Main Authors: Taylor, K.H, Middlefell, L.S, Mizen, K.D
Format: Article
Language:English
Subjects:
Anti-Infective Agents, Local - therapeutic use
Anti-RANKL
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Carcinoma - drug therapy
Chlorhexidine - therapeutic use
Denosumab
Dentistry
Diseases of the osteoarticular system
Humans
Laryngeal Neoplasms - drug therapy
Male
Mandibular Diseases - chemically induced
Medical sciences
Middle Aged
Mouthwashes - therapeutic use
Osteonecrosis
Osteonecrosis - chemically induced
Otorhinolaryngology. Stomatology
RANK Ligand - adverse effects
Surgery
Vascular bone diseases
Wound Healing - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear factor-κB ligand) such as denosumab (Prolia™, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases. We report a case of osteonecrosis that was induced by anti-RANKL therapy. To our knowledge this is the first case to have been induced by these agents.
ISSN:0266-4356
1532-1940
DOI:10.1016/j.bjoms.2009.08.030